Skip to main content
. Author manuscript; available in PMC: 2022 Mar 26.
Published in final edited form as: Ann Intern Med. 2020 Jun 23;173(4):320–322. doi: 10.7326/M20-0410

Figure. Participation-to-prevalence ratio (PPR) of African Americans in clinical trials supporting U.S. Food and Drug Administration approval of cancer drugs from 2014 to 2018.

Figure.

A PPR of 0.8 to 1.2 reflects similar representation of African American persons in the trial and disease populations. Hematologic cancer includes leukemia, lymphoma, and myelodysplastic syndrome. Results for multiple myeloma are expressed separately. Results for leukemia are expressed as part of hematologic cancer and also separately.